Endocyte Inc. (ECYT) Stock Rating Reaffirmed by Credit Suisse Group AG
Endocyte Inc. (NASDAQ:ECYT)‘s stock had its “buy” rating reissued by equities researchers at Credit Suisse Group AG in a report released on Friday. They presently have a $7.00 target price on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective suggests a potential upside of 137.29% from the stock’s current price.
Separately, Zacks Investment Research cut Endocyte from a “hold” rating to a “sell” rating in a research report on Wednesday, August 10th.
Shares of Endocyte (NASDAQ:ECYT) opened at 2.95 on Friday. The firm has a 50-day moving average of $3.00 and a 200-day moving average of $3.24. The company’s market capitalization is $124.69 million. Endocyte has a 12 month low of $2.62 and a 12 month high of $4.94.
Endocyte (NASDAQ:ECYT) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. The business had revenue of $0.03 million for the quarter. Endocyte had a negative return on equity of 25.17% and a negative net margin of 57,108.57%. The business’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.24) earnings per share. On average, equities analysts predict that Endocyte will post ($1.10) earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in ECYT. Baker BROS. Advisors LP acquired a new position in Endocyte during the third quarter valued at about $2,685,000. JPMorgan Chase & Co. raised its position in Endocyte by 30,170.2% in the second quarter. JPMorgan Chase & Co. now owns 782,485 shares of the biopharmaceutical company’s stock valued at $2,512,000 after buying an additional 779,900 shares during the last quarter. BlackRock Fund Advisors raised its position in Endocyte by 8.8% in the third quarter. BlackRock Fund Advisors now owns 1,698,464 shares of the biopharmaceutical company’s stock valued at $5,248,000 after buying an additional 137,032 shares during the last quarter. Bellevue Group AG acquired a new position in Endocyte during the first quarter valued at about $310,000. Finally, D. E. Shaw & Co. Inc. raised its position in Endocyte by 28.4% in the third quarter. D. E. Shaw & Co. Inc. now owns 331,591 shares of the biopharmaceutical company’s stock valued at $1,025,000 after buying an additional 73,371 shares during the last quarter. Hedge funds and other institutional investors own 36.58% of the company’s stock.
Receive News & Stock Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related stocks with our FREE daily email newsletter.